Open AccessThis article is
- freely available
CCR5: From Natural Resistance to a New Anti-HIV Strategy
Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, via Stamira D’Ancona, 20, 20127 Milan, Italy
Received: 23 October 2009; in revised form: 22 December 2009 / Accepted: 4 February 2010 / Published: 5 February 2010
Abstract: The C-C chemokine receptor type 5 (CCR5) is a key player in HIV infection due to its major involvement in the infection process. Investigations into the role of the CCR5 coreceptor first focused on its binding to the virus and the molecular mechanisms leading to the entry and spread of HIV. The identification of naturally occurring CCR5 mutations has allowed scientists to address the CCR5 molecule as a promising target to prevent or limit HIV infection in vivo. Naturally occurring CCR5-specific antibodies have been found in exposed but uninfected people, and in a subset of HIV seropositive people who show long-term control of the infection. This suggests that natural autoimmunity to the CCR5 coreceptor exists and may play a role in HIV control. Such natural immunity has prompted strategies aimed at achieving anti-HIV humoral responses through CCR5 targeting, which will be described here.
Keywords: CCR5; HIV; vaccine
Citations to this Article
Cite This Article
MDPI and ACS Style
Lopalco, L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses 2010, 2, 574-600.
Lopalco L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses. 2010; 2(2):574-600.
Lopalco, Lucia. 2010. "CCR5: From Natural Resistance to a New Anti-HIV Strategy." Viruses 2, no. 2: 574-600.